Abstract
Chronic kidney disease (CKD) is a silent disease which worsens gradually to end-stage kidney disease (ESKD). US kidney disease outcomes quality initiative (KDOQI) guidelines indicate five stages of CKD based on the severity of kidney function which is assessed by estimating the glomerular filtration rate (GFR) by the modification of diet in renal disease (MDRD) formula. The management of CKD patients with mild renal damage (stage 1–2 KDOQI) is articulated on the reduction of proteinuria (<500 mg/day), reduction of sitting systolic and diastolic blood pressure (<130/80 mmHg), salt restriction diet, diuretics (furosemide, spironolactone), antihypertensive agents (ACE inhibitors or ARBs (angiotensin II receptor blockers) or both as first-line therapy), additional other antihypertensives (aliskiren, non-dihydropyridine calcium channel blockers, beta blockers), body weight reduction, cigarette smoking stopping, allopurinol therapy and non-use of some drugs (non-steroidal anti-inflammatory agents, acetaminophen, bisphosphonates, oral estrogens) and herbals. The management of CKD patients with moderate-severe renal damage (stage 3–5 KDOQI) is based on the above recommendations plus low protein diet, correction of hyperkalaemia, metabolic acidosis, and administration of vitamin D derivates and erythropoietin for the correction of mineral metabolism disorders and anemia, respectively. In conclusion, patients with CKD (stage 1–2 KDOQI) may be correctly managed by primary care physicians, individuals in stage 3–5 KDOQI need the supervision of nephrologists to assess those patients who progress to ESKD and require renal replacement therapy.
Similar content being viewed by others
References
National Kidney Foundation (2002) KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 1):S1–S266
Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P (2005) Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16:763–773
Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483
Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang YL, Coresh J, Levey AS (2009) Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75:652–660
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252–1256
Hallan S, Asberg A, Lindberg M, Johnsen H (2004) Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 44:84–93
National Kidney Foundation (2002) KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 2):S1–S266
Carattino MD, Passero CJ (2011) Clues to renal sodium retention. Am J Physiol Renal Physiol 300:F639–F640
Choi ME (2009) The not-so-sweet side of fructose. J Am Soc Nephrol 20:457–459
Cianciaruso B, Bellizzi V, Minutolo R, Colucci G, Bisesti V, Russo D, Conte G, De Nicola L (1996) Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. J Am Soc Nephrol 7:306–313
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:542–551
Beddhu S (2004) The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. Semin Dial 17:229–232
Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004) The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141:95–101
Hallan SI, Orth SR (2011) Smoking is a risk factor in the progression to kidney failure. Kidney Int [Epub ahead of print]
Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557–1563
Arici M, Erdem Y (2009) Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 53:332–345
Cravedi P, Ruggenenti P, Remuzzi G (2009) Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep 11:118–124
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939–945
Anderson S, Komers R (2008) Aliskiren combined with losartan in diabetes and nephropathy. N Engl J Med 359:1069
Gashti CN, Bakris GL (2004) The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 13:155–161
Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905–1913
Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393
McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226–232
Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O (2001) Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345:1801–1808
Menon V, Kopple JD, Wang X, Beck GJ, Collins AJ, Kusek JW, Greene T, Levey AS, Sarnak MJ (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 53:208–217
Thompson AM, Pickering TG (2006) The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease. Kidney Int 70:1000–1007
Fink JC (2010) Chronic kidney disease: the effect of CKD therapies on serum potassium levels. Nat Rev Nephrol. 6:633–634
Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16:1803–1810
Weisbord SD, Kimmel PL (2008) Health-related quality of life in the era of erythropoietin. Hemodial Int 12:6–15
Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388
Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC (2007) Haemoglobin targets: we were wrong, time to move on. Lancet 369:346–350
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953
Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J (2004) Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 65:1031–1040
de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schena, F.P. Management of patients with chronic kidney disease. Intern Emerg Med 6 (Suppl 1), 77 (2011). https://doi.org/10.1007/s11739-011-0688-2
Published:
DOI: https://doi.org/10.1007/s11739-011-0688-2